Literature DB >> 21303476

The use of opioids in fibromyalgia.

Gene-Siew Ngian1, Emma K Guymer, Geoffrey O Littlejohn.   

Abstract

Fibromyalgia syndrome (FMS) is a chronic disorder of widespread pain with high personal and societal burdens. Although targeted pharmacotherapies have become available in recent years, it remains a challenging condition to treat. Despite no randomized controlled trials addressing the short- or long-term use of opioids in FMS, their use remains prevalent. In this article we discuss the role of opioids and other analgesics in the management of FMS, with particular focus on problems associated with their use. We review aspects of the pathophysiology of FMS and consider how specific factors may contribute to the lack of efficacy of opioids in this condition. Finally, we discuss drugs with combined opioid and anti-opioid action and their roles in FMS. There is insufficient evidence to recommend the routine use of opioids in FMS. As well as having a significant adverse effect profile, their inefficacy may be due to their inability to target the pathophysiologic processes involved in this central sensitization syndrome.
© 2010 The Authors. International Journal of Rheumatic Diseases © 2010 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21303476     DOI: 10.1111/j.1756-185X.2010.01567.x

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  18 in total

Review 1.  An overview of treatment approaches for chronic pain management.

Authors:  Nicholas Hylands-White; Rui V Duarte; Jon H Raphael
Journal:  Rheumatol Int       Date:  2016-04-23       Impact factor: 2.631

Review 2.  Fibromyalgia: Treating Pain in the Juvenile Patient.

Authors:  Sabrina Gmuca; David D Sherry
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

3.  Healthcare Costs Associated With Chronic Opioid Use and Fibromayalgia Syndrome.

Authors:  Jacob T Painter; Leslie J Crofford; J S Butler; Jeffery Talbert
Journal:  Am J Pharm Benefits       Date:  2015-02-13

Review 4.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

Review 5.  What are we treating with chronic opioid therapy?

Authors:  Daniel Krashin; Mark Sullivan; Jane Ballantyne
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

6.  Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia.

Authors:  Craig White; Winghan Jacqueline Kwong; Hilary Armstrong; Michael Behling; Jeffrey Niemira; Kathy Lang
Journal:  Am Health Drug Benefits       Date:  2018-09

Review 7.  Juvenile primary fibromyalgia syndrome: A Review- Treatment and Prognosis.

Authors:  Maya Levy Coles; Yosef Uziel
Journal:  Pediatr Rheumatol Online J       Date:  2021-05-18       Impact factor: 3.054

8.  Does association of opioid use with pain and function differ by fibromyalgia or widespread pain status?

Authors:  Judith A Turner; Susan M Shortreed; Kathleen W Saunders; Linda LeResche; Stephen Thielke; Michael Von Korff
Journal:  Pain       Date:  2016-10       Impact factor: 7.926

9.  Additive Complex Ayurvedic Treatment in Patients with Fibromyalgia Syndrome Compared to Conventional Standard Care Alone: A Nonrandomized Controlled Clinical Pilot Study (KAFA Trial).

Authors:  Christian S Kessler; Thomas Ostermann; Larissa Meier; Elmar Stapelfeldt; Silvia Schütte; Joachim Duda; Andreas Michalsen
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-01       Impact factor: 2.629

10.  Evaluation of the effectiveness of pregabalin in alleviating pain associated with fibromyalgia: using functional magnetic resonance imaging study.

Authors:  Seong-Ho Kim; Youngho Lee; Sunggun Lee; Chi-Woong Mun
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.